Hospital General Universitario Morales Meseguer
- Address
- lock Available on a paid plan
Hematologic Malignancies
The department at Hospital General Universitario Morales Meseguer conducts extensive research on blood‑related cancers, aiming to improve treatment outcomes and explore novel therapeutic combinations. Current studies focus on multiple myeloma and acute myeloid leukemia.
- Evaluation of new antibody‑drug conjugates in multiple myeloma
- Comparative studies of targeted kinase inhibitors for chronic myelogenous leukemia
- Trials assessing combination regimens in diffuse large B‑cell lymphoma
- Investigation of novel immunotherapies for acute myeloid leukemia
With 85 active trials and a strong investigator team, the department seeks to bring effective, less toxic options to patients with hematologic cancers.
Immune‑mediated Cytopenias
Research focuses on disorders where the immune system attacks blood cells, testing therapies that restore normal counts and reduce dependence on steroids. Studies include romiplostim combined with dexamethasone and the use of ianalumab for warm autoimmune hemolytic anemia.
- Safety and efficacy of romiplostim plus dexamethasone in primary immune thrombocytopenia
- Evaluation of ianalumab for durable hemoglobin response in warm autoimmune hemolytic anemia
- Study of povetacicept in patients with autoimmune cytopenias
- Comparison of standard care versus novel agents in immune thrombocytopenia
These trials aim to provide lasting remission and improve quality of life for patients with chronic immune‑driven blood disorders.
Breast Cancer Innovations
A broad portfolio of studies targets hormone‑receptor positive, HER2‑negative and triple‑negative breast cancers, evaluating new targeted agents and combination strategies. The work includes ribociclib added to endocrine therapy and inavolisib with HER2‑targeted treatment.
- Adding ribociclib to endocrine therapy in early HR+/HER2‑negative disease
- Testing inavolisib with HER2‑targeted therapy in PIK3CA‑mutant tumors
- Comparing trastuzumab deruxtecan versus trastuzumab emtansine in high‑risk HER2‑positive disease
- Assessing fezolinetant for relief of vasomotor symptoms during endocrine treatment
The goal is to increase disease‑free survival while managing treatment‑related side effects for diverse breast cancer subtypes.
Lung and Thoracic Oncology
Clinical trials address both non‑small cell lung cancer and related thoracic conditions, focusing on targeted therapies and immunotherapy combinations. Investigations feature osimertinib plus chemotherapy and novel anti‑PD‑L1 regimens.
- Comparing osimertinib plus chemotherapy versus chemotherapy alone in NSCLC
- Evaluating anti‑PD‑L1 therapy combined with chemotherapy in metastatic NSCLC
- Investigating the role of supplemental oxygen in acute pulmonary embolism management
- Study of ociperlimab with tislelizumab versus pembrolizumab in PD‑L1‑selected NSCLC
These studies aim to extend survival and improve symptom control for patients with advanced lung disease.
Gastrointestinal and Hepatobiliary Cancers
Trials explore innovative treatments for gastric, pancreatic, and neuroendocrine tumors, integrating targeted agents with standard chemotherapy. Notable agents include bemarituzumab for FGFR2b‑positive gastric cancer and cam2029 for metastatic neuroendocrine tumors.
- Evaluating bemarituzumab plus mFOLFOX6 in FGFR2b‑positive gastric cancer
- Assessing cam2029 versus octreotide in metastatic gastroenteropancreatic neuroendocrine tumors
- Testing ABTL0812 combined with FOLFIRINOX in metastatic pancreatic adenocarcinoma
- Comparing sacituzumab govitecan with physician’s choice in triple‑negative breast cancer with gastrointestinal involvement
The research seeks to improve progression‑free survival and offer new options for patients with difficult‑to‑treat gastrointestinal malignancies.
Transplantation and Graft‑versus‑Host Disease
Focused studies investigate prevention and treatment of complications after allogeneic stem cell transplantation, including immune modulation and infection control. Projects evaluate alpha‑1 antitrypsin for acute GVHD prevention and strategies against cytomegalovirus reactivation.
- Assessing alpha‑1 antitrypsin for prevention of acute GVHD
- Monitoring cytomegalovirus infection post‑transplant with prophylactic strategies
- Evaluating novel agents for treatment‑resistant gastrointestinal acute GVHD
- Comparing outcomes of different conditioning regimens in hematopoietic cell transplantation
These efforts aim to reduce transplant‑related mortality and enhance long‑term graft function for patients undergoing hematopoietic stem cell transplantation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 168 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 161 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 40 by active trials.
- 1Regeneron Pharmaceuticals Inc.2active
lock +39 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fundacion PETHEMA6trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital General Universitario Morales Meseguer
lock Showing 1 of 100 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 168 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 11 | Unknown | 2015-06-15 | 2024-11-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.